|
|
|
|
|
|
|
|
The Lancet Oncology, Early Online Publication, 22 August 2011
doi:10.1016/S1470-2045(11)70214-5Cite or Link Using DOI
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
"...
Findings
91
patients were enrolled (65 with ovarian cancer and 26 breast cancer)
and 90 were treated between July 8, 2008, and Sept 24, 2009. In the
ovarian cancer cohorts, 64 patients received treatment. 63 patients had
target lesions and therefore were evaluable for objective response as
per RECIST. In these patients, confirmed objective responses were seen
in seven (41%; 95% CI 22—64) of 17 patients with BRCA1 or BRCA2
mutations and 11 (24%; 14—38) of 46 without mutations. No confirmed
objective responses were reported in patients with breast cancer. The
most common adverse events were fatigue (45 [70%] of patients with
ovarian cancer, 13 [50%] of patients with breast cancer), nausea (42
[66%] and 16 [62%]), vomiting (25 [39%] and nine [35%]), and decreased
appetite (23 [36%] and seven [27%])...."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.